Involvement of serotonergic system in the antidepressant-like effect of hyperoside from Apocynum venetum leaves

Latin American Journal of Pharmacy

Volumn 31, Issue 7, 2012, Pages 984-989

  Zheng, Meizhu ^a   Liu, Chunming ^a   Fan, Yajun ^a   Shi, Dongfang ^a  

^a CHANGCHUN NORMAL UNIVERSITY   (China)

Author keywords

Antidepressant like effect; Apocynum venetum; Hyperoside

Indexed keywords

FLUOXETINE; HYPERIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; APOCYNUM; APOCYNUM VENETUM; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMOBILITY TIME; LOCOMOTION; MOUSE; NONHUMAN; OPEN FIELD TEST; PLANT LEAF; SEROTONINERGIC SYSTEM; TAIL SUSPENSION TEST; TIME;

EID: 84869218625     PISSN: 03262383     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wong M.L. & J. Licinio (2001) Rev. Neurosci. 2: 343-51.
2. Linde K. & L. Knuppel (2005) Phytomedicine 12: 148-57.
3. Zhangn, Z. J (2004) Life Sci. 75: 1659-99.
4. Grundmann, O., J. Nakajima & K. Kamata (2009) Phytomedicine 16: 295-302
5. Capra, J.C., M.P. Cunha, D.G. Machado, A.D.E. Zomkowski, B.G. Mendes, A.R.S. Santos et al. (2010) Eur. J. Pharmacol. 643: 232-8.
6. Sugimoto, Y., S. Furutani., K. Nishimura, A. Itoh, T. Tanahashi, H. Nakajima et al. (2010) Eur. J. Pharmacol. 634: 62-7
7. Papakostas, G.I. (2006) Neuropsychopharmacol. 16: 391-402.
8. Zhang, Y.C., C.M. Liu & Z. Zhang (2010) J Chromatogr B 878: 3149-55.
9. Steru, L., R. Chermat, B. Thierry & P. Simon (1985) Psychopharmacology (Berl.) 85: 367-70.
10. Porsolt, R.D., A. Bertin & M. Jalfre (1977) Arch. Int. Pharmacodyn. Thér. 229: 327-36.
11. Yi, L.T., C.F. Li, X. Zhan, C.C. Cui, F. Xiao, L.P. Zhou et al. (2010) Prog. Neuropsychopharmacol. Biol. Psychiatry 34: 1223-8.
12. Kiss, P.J. (2008) Neurochem. Int. 52: 34-9.
13. Nestler, E.J., M. Barrot, R.J. Dileone, A.J. Eisch, S.J. Gold & L.M. Monteggia (2002) Neuron 34: 13-25.
14. Racagni, G. & M. Popoli (2010) Int. Clin. Psychopharmacol. 25: 117-31.
15. Rénéric, J.P. & I. Lucki (1998) Psychopharmacology (Berl) 136: 190-7.
16. Machado, D.G., L.E. Bettio & M.P. Cunha (2009) Prog. Neuro-Psychoph. 33: 642-50.
17. Schildkraut, J.J. (1965) Am. J. Psychiat. 122: 509-22.
18. Heninger, G.R., P.L. Delgado & D.S. Charney (1996) Pharmacopsychiatry 29: 2-11.
19. Malagié, I., D.J. David & P. Jolliet (2002) Eur. J. Pharmacol. 443: 99-104.
20. Gordon, J.A. & R. Hen (2004) Annu. Rev. Neurosci. 27: 193-222.
21. Grimaldi, B., A. Bonnin & M.P. Fillion (1999) Neuroscience 93:1223-5.
22. Gross, C., L. Santarelli & D. Brunner (2000) Biol. Psychiat. 48: 1157-63.
23. Hensler, J.G. (2002) Neuropsychopharmacology 26: 565-73.
24. Brocardo, P.S., J. Budni & M. P Kaster (2008) Neuropharmacology 54: 464-73.
25. Mayorga, A.J., A. Dalvi, M.E. Page, S. Zimov-Levinson, R. Hen & I Lucki (2001) J. Pharmacol. Exp. Ther. 298: 1101-7.
26. Detke, M.J., S. Wieland & I. Lucki (1995) Psychopharmacology 119: 47-54.
27. Elhwuegi, A.S. (2004) Prog. Neuro-Psychoph. 28: 435-51.
28. Celada, P., M. Puig, M. Amargós-Bosch, A. Adell & F. Artigas (2004) J. Psychiat. Neurosci. 29: 252-65.
29. Zomkowski, A.D.E., A.O. Rosa, J Lin, A. R Santos, J.B. Calixto & A L.S. Rodrigues (2004) Brain Res. 1023: 253-63.
30. Artigas, F. (2002) Eur. Neuropsychopharmacol. 12: 166-7.
31. Rosel, P., B. Arranz, L. San, J. Vallejo, J.M. Crespo, M. Urretavizcaya et al. (2000) Psychiatr. Res. 99: 173-81.
32. Yates, M., A. Leake, J.M. Candy, A.F. Fairbairn, I.G. McKeith & I.N. Ferrier (1990) Biol. Psychiat. 27: 489-96.
33. Kang, S.Y., E.J. Park, W.K. Park, H.J. Kim, G. Choi, M.E. Jung et al. (2010) Bioorg. Med. Chem. 18: 6156-9.